News

Formosa Pharmaceuticals and AimMax Therapeutics ReceiveFDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for theTreatment of Post-Operative Inflammation and Pain Following Ocular Surgery   TAIPEI – March 4, 2024 – Taiwan-based Formosa Pharmaceuticals (6838.TWO) and AimMax Therapeutics (United States) announced today that the U.S. Food and Drug Administration (FDA) has approved clobetasol propionate ophthalmic suspension …

Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery Read More »

Formosa Pharmaceuticals Announces Licensing Agreement with Cristália, for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery TAIPEI – January 26, 2024 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TWO) announced today that the company has entered into a licensing agreement with CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA (“Cristália”), for exclusive Brazilian rights to …

Formosa Pharmaceuticals Announces Licensing Agreement with Cristália, for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery Read More »

TAIPEI – August 16, 2023 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TWO) announced today that the company has entered into a licensing agreement with Eyenovia, Inc. (“Eyenovia”, NASDAQ: EYEN), whereby Eyenovia obtains exclusive U.S. rights for the commercialization of APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) for the treatment of inflammation and pain following ocular surgery.  APP13007 …

Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery Read More »

July 5th, 2023 TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (6838.TWO) announce the United States Food & Drug Administration (US FDA) acceptance of its New Drug Application for APP13007, a novel aqueous nanosuspension formulation of the potent corticosteroid, clobetasol propionate (0.05%), for the treatment of inflammation and pain following ocular surgery.  The FDA has assigned a …

Formosa Pharmaceuticals Announce FDA Acceptance of NDA Filing for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery Read More »

May 5th, 2023 TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) announce the submission of a New Drug Application to the United States Food & Drug Administration (US FDA) for APP13007, a novel aqueous nanosuspension formulation of the potent corticosteroid, clobetasol propionate (0.05%), for the treatment of inflammation and pain …

Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery Read More »

February 15th, 2023 The collaboration will combine Formosa’s proprietary APNT™ nanoparticle formulation platform with Eyenovia’s Optejet® dispensing technology for the development of new ophthalmic therapies in high-value indications with significant unmet medical needs. TAIPEI – February 15, 2023 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TWO) announced today that the company has entered into a collaboration agreement …

Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia Read More »

January 31st, 2023 TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (6838.TWO) report a summary of integrated clinical results for APP13007, a novel ophthalmic nanosuspension formulation of the potent corticosteroid, clobetasol propionate (0.05%), for the treatment of inflammation and pain after cataract surgery.  Included in the summary results are Phase 2 clinical trials (CPN-201) and two parallel …

Formosa Pharmaceuticals Announce a Summary of Integrated Clinical Results for APP13007 for the Treatment of Inflammation and Pain after Cataract Surgery Read More »

November 8th, 2022 Taipei, Taiwan – Formosa Pharmaceuticals, Inc. (TWO.6838) and development partner, AimMax Therapeutics, Inc. (US), announced the completion of a pre-NDA meeting with the US FDA for its lead program, APP13007, a 14-day, twice-daily eyedrop for the treatment of inflammation and pain after ocular surgery.  The favorable outcome of the meeting lays the …

Formosa Pharmaceuticals, completes successful pre-NDA Meeting with the US FDA and plans for NDA submission of APP13007 Read More »

TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) report successful top-line results from CPN-302, the second of the two pivotal Phase 3 clinical studies of APP13007, a novel ophthalmic nanosuspension formulation of the potent corticosteroid, clobetasol propionate (0.05%), for the treatment of inflammation and pain after cataract surgery.  CPN-302 was …

Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery. Read More »

TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (TWO.6838) and Aimmax Therapeutics, Inc. (United States) announced that results from a Phase 2 clinical study of APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension), a novel formulation of the potent corticosteroid, clobetasol propionate, for the treatment of inflammation and pain after cataract surgery, will be presented at the 2022 Association for …

Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment of Inflammation and Pain after Cataract Surgery at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting Read More »